Review discusses ECM1's role in TGFβ activation, suggesting it may improve healing in chronic wounds and fractures.
Extracellular matrix protein1 (ECM1) plays a crucial role in the activation of latent transforming growth factorbeta (TGFβ). Active TGFβ governs key phases of tissue repair including inflammation, fibroblast activation, angiogenesis, and matrix remodeling. Dysregulation of TGFβ signaling is a hallmark of chronic wounds, excessive scar formation, and fracture non-union. As a protein of the extracellular matrix, ECM1 offers ideal conditions for the biofunctionalization of implants. Its mode of action has been studied mainly in fibrosis models, where TGFβ acts as driver of the disease. Controlled knock-out or over-expression of ECM1 either promoted or improved fibrosis development. In this review, we discuss how the findings can be applied to the biofunctionalization of implants to support the healing of skin and bone.
No takes yet. Share an insight, caveat, or question.
Braun et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: